Peptides9 min·Published May 25, 2026

Kisspeptin-10: How It Works, Uses, and What the Research Says

A patient guide to the peptide that controls the body's reproductive hormone switch — mechanism, evidence, safety, and access.

ByDr. Elena Vasquez
Clinically reviewed by Dr. Anika Rao
Kisspeptin-10: How It Works, Uses, and What the Research Says

Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.

See if you qualify →

Kisspeptin-10 is a 10-amino-acid peptide fragment of the KISS1 protein that signals the hypothalamus to release GnRH (gonadotropin-releasing hormone). GnRH then prompts the pituitary to release LH and FSH, the two hormones that drive testosterone, estradiol, ovulation, and sperm production. Researchers are studying kisspeptin-10 for fertility, hypogonadism, and low libido. It is not FDA-approved, and U.S. access is limited to clinical research and physician-supervised compounding [1][2].

What is kisspeptin-10?

Kisspeptin-10 is a short peptide — a chain of just 10 amino acids — made from a longer parent protein encoded by the KISS1 gene. The full kisspeptin family includes several fragments (kisspeptin-54, -14, -13, and -10), all of which share the same active C-terminal end and bind the same receptor, called KISS1R or GPR54 [1].

Scientists first described KISS1 as a metastasis-suppressor gene in the 1990s. In 2003, researchers found that people with inactivating mutations in KISS1R did not go through puberty, which revealed the KISS1/KISS1R pathway as the master switch for the reproductive hormone system [5]. Since then, kisspeptin has become one of the most studied peptides in reproductive endocrinology.

How does kisspeptin-10 work in the body?

The KISS1/KISS1R pathway

KISS1 neurons sit in two main areas of the hypothalamus: the arcuate nucleus and the anteroventral periventricular nucleus. When these neurons release kisspeptin, it binds KISS1R on nearby GnRH neurons. That binding is the upstream trigger that wakes up the entire hypothalamic-pituitary-gonadal (HPG) axis [1][5].

Effect on GnRH, LH, and FSH

Once kisspeptin-10 activates GnRH neurons, they release GnRH in pulses. GnRH travels a short distance to the pituitary gland, which responds by releasing luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH and FSH then act on the testes or ovaries to make testosterone, estradiol, sperm, or eggs [1][3].

In clinical studies, a single intravenous dose of kisspeptin-10 reliably raises LH within minutes in healthy men and women, and the LH response typically peaks around 30–60 minutes after dosing [3][6].

What is kisspeptin-10 used for?

Fertility and reproductive function

The most studied use is as an egg-maturation trigger in IVF. In trials at Imperial College London, kisspeptin (mostly the -54 form, with kisspeptin-10 in earlier work) was investigated in place of the standard hCG trigger and supported egg maturation and live births, with researchers reporting a possibly lower risk of ovarian hyperstimulation syndrome (OHSS) compared with hCG in those studies [4][7]. Kisspeptin is also being studied in women with hypothalamic amenorrhea — a condition where the brain stops signaling the ovaries [6]. Side effects in these studies included mild headache, transient flushing, and brief cardiovascular changes during infusion [3][6].

Low testosterone and libido

In men with hypogonadotropic hypogonadism (low testosterone caused by a brain-level signaling problem), short kisspeptin infusions have raised LH and testosterone in small studies [3]. Early research in men with hypoactive sexual desire also reported increased brain activity in sexual-arousal regions after kisspeptin administration [8]. These are early signals, not proof of long-term benefit. No head-to-head trials show kisspeptin-10 outperforms approved testosterone therapies, and long-term safety is unknown. Kisspeptin-10 is not approved for low testosterone or low libido, and should not be considered a substitute for evaluation of underlying causes.

Research uses

Endocrinologists also use kisspeptin-10 as a diagnostic probe — a way to test whether someone's GnRH neurons can still respond — and as a research tool to map the HPG axis.

Kisspeptin-10 vs kisspeptin-54: what's the difference?

Both peptides bind the same receptor and trigger the same downstream LH and FSH response. The main differences are length, how long they stay active in the body, and how researchers have used them.

FeatureKisspeptin-10Kisspeptin-54
Length10 amino acids54 amino acids
Plasma half-life~3–4 minutes [2]~28 minutes [2]
Onset of LH riseRapid (within minutes)Rapid (within minutes)
Duration of effectShort — often given as infusionLonger — single bolus can work
Most studied inMechanistic and dosing studies, hypogonadismIVF trigger, hypothalamic amenorrhea
FDA approvalNoneNone

In research settings, kisspeptin-10 is often selected when investigators want a short, controllable signal; kisspeptin-54 is preferred when a longer-lasting LH surge is needed, such as triggering egg maturation in IVF [4][7].

What does the research say about kisspeptin-10?

Kisspeptin-10 has been tested in dozens of small clinical studies, mostly Phase 1 and Phase 2. Consistent findings: it reliably raises LH and FSH in healthy adults, it restores LH pulses in some forms of hypogonadism, and it appears well tolerated at the short-term, low doses studied [3][6][8]. What is not yet known is whether long-term, repeated dosing is safe, whether tolerance develops, and whether it improves real-world fertility outcomes outside controlled IVF protocols. Off-label and compounded use for general 'libido' or 'longevity' purposes is currently being studied and is not supported by long-term safety data.

How is kisspeptin-10 dosed and administered?

This article does not provide individual dosing guidance — that requires a clinician who knows your medical history. For educational context only: published research has most often used kisspeptin-10 as a continuous intravenous infusion or as repeated subcutaneous injections, because of its very short half-life [2][3]. Typical research doses have ranged widely depending on the goal (diagnostic test, GnRH stimulation, or sustained signal). Any clinical use outside a trial should be supervised by a physician who can monitor LH, FSH, testosterone or estradiol, and symptoms, and weigh the unknown long-term risks.

What are the side effects and safety considerations?

In short-term studies, kisspeptin-10 has generally been well tolerated. Reported effects include mild injection-site reactions, transient headache, flushing, and brief changes in heart rate or blood pressure during infusion [3][6]. Because kisspeptin powerfully activates the reproductive axis, important risks and contraindications to consider include:

  • Unintended changes in menstrual cycles, ovulation, or fertility.
  • Possible hormonal effects in people with hormone-sensitive cancers (breast, prostate, ovarian) — generally a reason to avoid.
  • Unknown effects during pregnancy and breastfeeding — should be avoided in these groups.
  • Unknown long-term safety with repeated, chronic dosing.
  • Quality, purity, and sterility risks with non-pharmacy 'research-only' peptides sold online.

Is kisspeptin-10 FDA approved?

No. Kisspeptin-10 is not FDA-approved for any condition. In the United States, it is used in clinical research or prepared by 503A compounding pharmacies for individual patients when a physician determines it is clinically appropriate. 503A pharmacies make patient-specific medications under state pharmacy board oversight; they are not the same as FDA-approved drug manufacturers, and compounded peptides do not undergo the same large-scale efficacy and safety review [9].

How to access kisspeptin-10 through a licensed provider

If you and your clinician decide kisspeptin-10 is worth exploring, there are several legitimate paths in the U.S.:

  1. 1Enroll in a clinical trial through a research center or via ClinicalTrials.gov.
  2. 2See a reproductive endocrinologist or men's health specialist who can evaluate the underlying issue (low testosterone, irregular cycles, infertility) and discuss whether kisspeptin-10 or an approved alternative is appropriate.
  3. 3Work with a licensed telehealth provider that partners with a 503A compounding pharmacy. Chia is one such option — our clinicians review your labs, history, and goals, and only prescribe compounded peptides when clinically appropriate. We are one of several licensed paths, not the only one.

Whichever path you choose, the right starting point is a real clinical evaluation — bloodwork (LH, FSH, testosterone or estradiol, prolactin), a symptom history, and a conversation about goals and risks. Peptide therapy without that workup is not appropriate.

3-min quiz

Talk to a Chia clinician about peptide therapy

If you are exploring kisspeptin-10 or other peptides for fertility, low testosterone, or libido, a licensed clinician can review your labs and help you decide whether it is a fit — or whether an approved therapy would serve you better. Individual results vary, and eligibility depends on clinical review.

Frequently asked questions

3-min quiz

Curious whether peptide therapy fits your goals?

Chia's clinicians offer telehealth evaluations for compounded peptide and GLP-1 therapy when clinically appropriate. Eligibility depends on clinical review and individual results vary.

References

  1. 1.Pinilla L, Aguilar E, Dieguez C, Millar RP, Tena-Sempere M. Kisspeptins and reproduction: physiological roles and regulatory mechanisms. Physiological Reviews. 2012;92(3):1235-1316.
  2. 2.Jayasena CN, Nijher GMK, Comninos AN, et al. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. Journal of Clinical Endocrinology & Metabolism. 2011;96(12):E1963-E1972.
  3. 3.Dhillo WS, Chaudhri OB, Patterson M, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. Journal of Clinical Endocrinology & Metabolism. 2005;90(12):6609-6615.
  4. 4.Abbara A, Jayasena CN, Christopoulos G, et al. Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of OHSS during IVF therapy. Journal of Clinical Endocrinology & Metabolism. 2015;100(9):3322-3331.
  5. 5.Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. New England Journal of Medicine. 2003;349(17):1614-1627.
  6. 6.Jayasena CN, Abbara A, Comninos AN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. Journal of Clinical Investigation. 2014;124(8):3667-3677.
  7. 7.Abbara A, Clarke SA, Dhillo WS. Clinical potential of kisspeptin in reproductive health. Trends in Molecular Medicine. 2021;27(8):807-823.
  8. 8.Comninos AN, Wall MB, Demetriou L, et al. Kisspeptin modulates sexual and emotional brain processing in humans. Journal of Clinical Investigation. 2017;127(2):709-719.
  9. 9.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA.gov.

About this article

Dr. Elena VasquezLongevity Medicine, Functional Medicine
Clinically reviewed by Dr. Anika RaoEndocrinology, MD

This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.

Get a personalized plan

See if GLP-1 is right for your body.

Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.

Take the 3-min quiz

Keep reading

Back to all guides